Furthermore, combination treatment of crizotinib and EGFR inhibitor gefitinib disrupts cell proliferation and invasion significantly more than inhibition of each pathway alone in HNSCC cell lines [130]. Here, EGFR is linked to head and neck squamous cell carcinoma.